Nine oncology practices certified through ASCO Patient-Centered Cancer Care Certification pilot

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Nine outpatient oncology group practices have achieved certification through the new American Society of Clinical Oncology Patient-Centered Cancer Care Certification pilot. 

The ASCO Certification Program awarded certification to the first group of participants, including: Cancer & Hematology Centers of Western Michigan, Central Georgia Cancer Care, Hematology-Oncology Associates of CNY, Jefferson Health-Sidney Kimmel Cancer Center, Tennessee Oncology, The Center for Cancer and Blood Disorders, Nebraska Hematology-Oncology, PC, New England Cancer Specialists, and Memorial Cancer Institute.

“This first round of certifications is a major milestone for the success of this pilot, as it demonstrates that this new model for patient-centered cancer care delivery is achievable for all oncology practices, regardless of their practice setting,” Lori J. Pierce, chair of the Board of the Association for Clinical Oncology, said in a statement. 

The pilot includes 88 cancer care sites and nearly 500 oncologists from 12 participating practice groups and health systems. All pilot participants are on track to meet the standards and achieve certification in the coming months.

Certification is based on adherence to the Oncology Medical Home Standards: a single set of comprehensive, expert-backed standards for patient-centered care delivery, published by ASCO and the Community Oncology Alliance. 

The ASCO-COA Oncology Medical Home Standards focus on seven domains of cancer care, including: patient engagement; availability and access to care; evidence-based medicine; equitable and comprehensive team-based care; quality improvement; goals of care, palliative, and end-of-life care discussions; and chemotherapy safety.

To achieve certification, practices needed to meet a total of 17 care delivery standards and 22 chemotherapy safety standards, for a total of 39 standards.

The pilot is slated to end in summer 2023. 

Table of Contents

YOU MAY BE INTERESTED IN

“When I joined ASCO in 2001, the most important thing to me was networking. I savored the opportunities to come to the annual meeting to meet and to talk with those who had led the studies that would inform standards of care, particularly in gynecologic oncology,” said Don S. Dizon. 
Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center and the IU School of Medicine have discovered that Black patients with breast cancer who are treated with docetaxel experience less peripheral neuropathy. Their findings represent an important shift in knowledge about a patient population who’ve historically been underrepresented in breast cancer research.
Data from the IMROZ phase III trial demonstrated Sarclisa (isatuximab) in combination with standard-of-care bortezomib, lenalidomide and dexamethasone followed by Sarclisa-Rd (the IMROZ regimen) significantly reduced the risk of disease progression or death by 40%, compared to VRd followed by Rd in patients with newly diagnosed multiple myeloma not eligible for transplant. 

Login